Bevacizumab in metastatic colorectal cancer in a real-life setting – toxicity profile, survival outcomes, and impact of tumor sidedness

INTRODUCTION: Targeting angiogenesis in metastatic colorectal cancer (mCRC) using bevacizumab is a standard of care. The addition of this targeted biological agent to first-line infusional fluoropyrimidine-based chemotherapy was associated with superior overall survival (OS) in several randomized an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chibani, Hind, El Bairi, Khalid, Al Jarroudi, Ouissam, Afqir, Said
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052347/
https://www.ncbi.nlm.nih.gov/pubmed/35506031
http://dx.doi.org/10.5114/wo.2022.114678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052347/
https://www.ncbi.nlm.nih.gov/pubmed/35506031
http://dx.doi.org/10.5114/wo.2022.114678

Ejemplares similares